The Hematologist

banner image

Ask the Hematologist

Dr. Gary Lyman examines the safety and efficacy of biosimilars approved by the U.S. Food and Drug Administration.

Read more
banner image

A Story About a River Named Indus

Dr. Saad Usmani discusses "Empires of the Indus" by Alice Albinia, a nonfiction book about the author's travels along the river.

Read more
banner image


Drs. Kristen O'Dwyer and Wendy Stock discuss they CALGB 10403 Trial, which tests the efficacy and feasibility of a pediatric regimen for AYAs with newly diagnosed B- or T-lineage Philadelphia chromosome-negative ALL.

Play here
Current Issue Static Feature

Current Issue

May/June 2019
Volume 16, Issue 3

Read current issue
  • 2018 ASH Advocacy Activities
    December 11, 2018

    ASH continues to increase its efforts to expand and enhance the Society’s reach. NIH funding, efforts to ensure patient access to drugs, and sickle cell disease were top priorities on ASH’s advocacy agenda in 2018.

  • 2018 ASH Advocacy Efforts Related to Sickle Cell Disease and Sickle Cell Trait
    December 11, 2018

    ASH continues to invest in and explore the important actions needed to make a significant difference in sickle cell disease (SCD) access to care, research, and global issues. Learn about the major advocacy-related initiatives undertaken by ASH in 2018.

  • 2018 ASH Advocacy Efforts to Ensure Patient Access to Care
    December 11, 2018

    In 2018, ASH worked to ensure patient access to care through a number of methods including ensuring drug access, pain management-related issues, and the Affordable Care Act.

  • 2018 Physician Payment Advocacy Highlights
    December 11, 2018

    In 2018, ASH commented on numerous rules and regulations proposed by the Centers for Medicare and Medicaid Services (CMS), which impact physician payment. ASH is actively involved in various advisory committees and also continues to engage with lawmakers on Capitol Hill.

View all Policy News